Bioceltix S.A.
BCX.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.66 | 26.39 | -1.22 | 1.64 |
| FCF Yield | -1.17% | -0.44% | -0.16% | -1.01% |
| EV / EBITDA | -112.51 | -137.38 | -127.77 | -144.28 |
| Quality | ||||
| ROIC | -16.03% | -11.63% | -10.84% | -11.65% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.14 | 0.52 | 0.15 | 1.37 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -162.05% | -194.10% | 82.58% | 36.19% |
| Safety | ||||
| Net Debt / EBITDA | 5.57 | 8.42 | 9.01 | 11.88 |
| Interest Coverage | -127.57 | -84.08 | -77.81 | -79.74 |
| Efficiency | ||||
| Inventory Turnover | 4.86 | 0.00 | 33.72 | 14.95 |
| Cash Conversion Cycle | -905.44 | -238.00 | -551.74 | -635.99 |